Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03804814
Other study ID # SAIL-003
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 21, 2019
Est. completion date October 4, 2021

Study information

Verified date February 2023
Source Nova Scotia Health Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study addresses a difficult barrier to hepatitis C elimination, specifically development and maintenance of a productive relationship between the health care provider and patient to ensure both treatment success and engagement in harm reduction services. Improvements in these domains may be observed through the use of a technique called "Motivational Interviewing" (MI). The aim of this study is to determine whether a customized motivational interviewing curriculum by general primary care and addictions medicine primary care providers changes rates of curative hepatitis C therapy completion.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date October 4, 2021
Est. primary completion date October 4, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Patient Inclusion Criteria: - Willingness to participate and provide informed consent - Positive HCV RNA Result - =18 years of age Patient Exclusion Criteria: - Unwilling or unable to provide consent Health Care Provider Inclusion Criteria: - Willingness to participate and provide informed consent - Has a hepatitis C care experience Health Care Provider Exclusion Criteria: - Unwilling or unable to provide consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Motivational Interviewing Training
Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions. A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers.

Locations

Country Name City State
Canada Nova Scotia Health Authority Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary HCV Treatment Completion To measure the number of patients who complete HCV therapy Through study completion, an average of 2 years
Secondary Time from care engagement to treatment initiation Through study completion, an average of 2 years
Secondary Number of unique Hepatitis C related and unrelated health system visits Through study completion, an average of 2 years
Secondary Number of scheduled and attended medical care appointments Through study completion, an average of 2 years
Secondary Self-reported intent to initiate and maintain HCV treatment assessed by questionnaire Through study completion, an average of 2 years
Secondary Healthcare provider knowledge, attitudes, and behavior about motivational interviewing and training assessed by questionnaire Through study completion, an average of 2 years
Secondary Time to complete prescribed HCV treatment course Through study completion, an average of 2 years
Secondary Percentage of eligible individuals that initiate HCV therapy Through study completion, an average of 2 years
See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Recruiting NCT04510246 - Link Hepatitis C Notifications to Treatment in Tasmania N/A
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda Phase 2
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Completed NCT03740230 - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT04405024 - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients N/A
Completed NCT04525690 - Improving Inpatient Screening for Hepatitis C N/A
Completed NCT04033887 - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Active, not recruiting NCT02961426 - Strategic Transformation of the Market of HCV Treatments Phase 2/Phase 3
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02992184 - PoC-HCV Genedrive Viral Detection Assay Validation Study N/A
Completed NCT03186313 - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3